Status:
UNKNOWN
Rifaximin Improves Gut Dysbiosis in Insulin Resistance and Type 2 Diabetes
Lead Sponsor:
Zagazig University
Conditions:
Type2 Diabetes
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
Gut Dysbiosis had been involved in some way in the pathogenesis of some extra-intestinal disorders including metabolic syndrome, cardiovascular disease, and obesity.
Detailed Description
Accumulating evidence had linked metabolic syndrome and diabetes to dysequilibrium in gut microbiota, which are a critical regulator of host metabolism and immune responses. gut microbiota interacts w...
Eligibility Criteria
Inclusion
- diabetes with gut dysbiosis
Exclusion
- recent antibiotic use
- pregnancy
- diabetogenic drugs
Key Trial Info
Start Date :
November 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2019
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT03758144
Start Date
November 1 2018
End Date
July 1 2019
Last Update
November 29 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zagazig University
Zagazig, Sharqia Province, Egypt, 44519